Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novo Nordisk A/S
Woman and Man Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to less than 6 Years Old) Subjects with Congenital FXIII A-subunit Deficiency
To characterise the pharmacokinetics of rFXIII in paediatric subjects (1 to less than 6 years old) with congenital FXIII A-subunit deficiency following a single intravenous dose administration by meas...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit
The primary objective is to evaluate the effect of Norditropin® on final height in children with Noonan syndrome
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Haemophilia B
To evaluate immunogenicity of N9-GP (nonacog beta pegol)
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
A 12 month, open-label, multi-center trial to investigate the endometrial safety of Vagifem Low Dose (10ug 17beta-estradiol vaginal tablet) in postmenopausal women with atrophic vaginitis symptoms. Trial Phase: IIIa
To evaluate the endometrial hyperplasia rate from endometrial biopsies taken at the beginning and at the end of study treatment (12 months).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
Efficacy and Safety of Oral Semaglutide versus Placebo in Subjects with Type 2 Diabetes Mellitus treated with insulin
To compare the effect of once-daily dosing of three dose levels of oral semaglutide (3, 7 and 14 mg) versus placebo on glycaemic control in subjects with type 2 diabetes mellitus treated with insulin...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes
To compare the effect of once-daily dosing of three dose levels (3 mg, 7 mg and 14 mg) of oral semaglutide versus sitagliptin 100 mg once-daily, both in combination with metformin with or without sulf...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage
The primary objective of this trial is to evaluate the efficacy of rFVIIa (NovoSeven®/Niastase®) in reducing disability and improving clinical outcome by preventing early haematoma growth in patients ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia A
To evaluate the safety of s.c. administration of turoctocog alfa pegol (SC N8-GP) in patients with severe haemophilia A
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
A trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function
The primary objective is to evaluate the effect of NNC0114-0006, liraglutide and the combination of NNC0114 0006 and liraglutide, compared to placebo, on preservation of beta-cell function after 54 we...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novo Nordisk A/S
Update Il y a 4 ans
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus 1.8 mg liraglutide subcutaneous and versus placebo, all in combination with metformin with or without a SGLT-2 inhibitor, on...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
5
6
7
8
9
10
11
12
13
14
Next